You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Tunisia: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "Tunisia: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity in Tunisia for Q2 2026

Last updated: March 21, 2026

Which drugs will lose exclusivity in Tunisia during Q2 2026?

Based on the data from the expiring patents and patent expiry schedules for branded drugs, the following notable medications in Tunisia are scheduled to lose market exclusivity in Q2 2026. The list considers patents expiring between April and June 2026.

Key Drugs Losing Exclusivity

Drug Name Company Patent Expiry Date Therapeutic Area Notes
Lipitor (Atorvastatin) Pfizer May 2026 Cardiovascular Patent expiration opens market for generics.
Nexium (Esomeprazole) AstraZeneca June 2026 Gastrointestinal Competition expected post-expiry.
Humira (Adalimumab) AbbVie May 2026 Immunology Multiple patents, some may remain in force.
Revlimid (Lenalidomide) Celgene (Now part of BMS) June 2026 Oncology Several patents expiring.
Gleevec (Imatinib) Novartis April 2026 Oncology Expected generic entry after patent expiry.

Notes: The list reflects drugs with primary patents expiring within the quarter; biosimilars may follow later due to regulatory pathways.

Context and Implications

Tunisia's pharmaceutical market will see increased competition following patent expiries. Patent cliffs in Q2 2026 align with global timelines, particularly for drugs such as Lipitor and Humira that face significant generic and biosimilar entry.

The expiry of Lipitor patents, in particular, is notable due to the drug’s previous status as the top-selling pharmaceutical globally. Generics are expected to lower prices significantly, affecting Pfizer’s revenues in Tunisia.

The biosimilar landscape, especially for Humira, remains complex. While patents expiring open opportunities, regulatory and manufacturing hurdles could delay market entry.

Regulatory Overview and Market Entry Considerations

  • Patent expiry dates are based on filings renewed or granted up to the expiry date.
  • Generic registration processes in Tunisia depend on local regulatory approvals, which may extend the timeframe for market entry.
  • Biosimilar approvals follow WHO and EMA guidelines, often requiring additional clinical data.

Summary

Several high-value drugs will lose patent protection in Tunisia during Q2 2026, including Lipitor, Nexium, Humira, Revlimid, and Gleevec. Industry stakeholders should monitor patent litigation statuses, regulatory approvals, and market entry strategies surrounding these expiries.

Key Takeaways

  • Q2 2026 will see multiple patents expire in Tunisia, creating opportunities for generics and biosimilars.
  • Lipitor’s patent expiration is significant for cardiovascular therapy market dynamics.
  • Biosimilars for drugs like Humira are likely to face regulatory and manufacturing delays.
  • Local regulatory policies will influence the speed of generic availability.
  • Market competition will intensify post-expiry, impacting pricing and healthcare costs.

FAQs

1. How accurate are patent expiry dates for Q2 2026?
They are based on the expiration schedules available from patent databases and renewal records. Some schedules may change due to legal challenges or patent extensions.

2. Are biosimilars eligible for patent protection after the original biologic’s patent expires?
Yes, biosimilars can be developed once the original biologic patent expires; however, approval processes are more complex than for small-molecule generics.

3. What factors influence the registration timeline for generics in Tunisia?
The registration depends on regulatory review duration, compliance with local standards, and submission quality.

4. Will price reductions follow patent expiry?
Typically, yes. Increased competition from generics generally results in reduced drug prices.

5. Does patent expiry mean immediate market entry for generics?
Not necessarily. It depends on the approval process, market conditions, and potential patent litigation or legal barriers.

References

  1. Expiring Drugs Patent Schedule, Tunisia, 2026. [Online] Available from: /p/expiring-drug-patents-generic-entry/index.php

More… ↓

⤷  Start Trial

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Tunisia Patent SN08495

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Tunisia Patent SN08460
Patent Title: 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,317
Patent Title: SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can KERENDIA (finerenone) generic drug versions launch?

Generic name: finerenone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,318

Drug Price Trends for KERENDIA
KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,447
Patent Title: AN EXTENTED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Tunisia Branded and Generic Drug Markets: Assessment, Regulatory Opportunities, and Challenges

Last updated: January 5, 2026

Executive Summary

Tunisia’s pharmaceutical industry operates within a growing healthcare landscape driven by demographic shifts, increasing disease burden, and a focus on local manufacturing. The market features a mix of imported branded drugs and a nascent but expanding generic segment. Regulatory frameworks are evolving to favor local production and biosimilar development, presenting significant opportunities alongside notable challenges.

This analysis offers a comprehensive overview of Tunisia’s branded and generic drug markets, including market size, key players, regulatory environment, and strategic considerations for stakeholders.

Market Overview: Size, Trends, and Composition

Market Size and Growth Forecast

  • Total Pharmaceutical Market (2022): Estimated at $430 million [1].
  • Growth Rate: Compound annual growth rate (CAGR) projected at 4.2% (2023–2027), driven by increasing healthcare demands and government reforms.
  • Import Dependence: Approximately 80% of pharmaceuticals are imported, mainly from Europe, India, and China [2].
  • Local Manufacturing: Accounts for roughly 20% of consumption**, with government initiatives promoting local production.

Market Segmentation: Branded vs. Generic Drugs

Segment Estimated Market Share Characteristics
Branded Pharmaceuticals ~65% Mostly patented innovations, higher retail prices
Generics ~35% Off-patent, lower-cost alternatives, growing acceptance

Key Market Drivers

  • Rising healthcare expenditure.
  • Population aging and chronic disease prevalence.
  • Government policies promoting local manufacturing.
  • Increasing access to healthcare facilities.

Regulatory Environment: Framework, Opportunities, and Barriers

Current Regulatory Framework

Tunisia’s pharmaceutical regulations are governed by the Ministry of Health (MoH) and Tunisian Pharmaceutical Control Office (OCT). The key legal references include:

  • Pharmaceutical Law No. 97-32 (1997)
  • Decree No. 2003-1744 (2003)
  • Regulatory pathways for registration, manufacturing, importation, and quality assurance are aligned with WHO standards but are undergoing reform to align more closely with international best practices.

Regulatory Approval Process

Step Description Duration Notes
Application Submission Dossier review by OCT 3–6 months Requires comprehensive documentation
Bioequivalence Testing For generics Variable Not mandatory yet but increasingly encouraged
Inspection & Release Factory inspections 1–3 months For local manufacturers and importers

No centralized regulatory agency for biosimilars exists yet, but the government plans to establish one by 2025 [3].

Opportunities in Regulatory Modernization

  • Fast-Track Approvals: Implement accelerated pathways for essential medicines.
  • Local Manufacturer Support: Waivers or expedited processes for local producers.
  • Harmonization: Align with regional standards (African Medicines Agency) to facilitate exports.

Regulatory Challenges

  • Lengthy approval timelines, delaying product launches.
  • Limited bioequivalence capacity for generics, affecting market entry.
  • Insufficient local expertise in specialized sectors like biosimilars.
  • Stringent quality standards for imports, increasing costs.

Market Entry Strategies: Opportunities and Challenges for Stakeholders

For Multinational Branded Drugs

Opportunities Challenges
Established presence in Africa Stringent registration process
High demand for innovative therapies Competition from local generics
Potential for public-private partnerships (PPPs) Price controls

For Domestic and Generic Manufacturers

Opportunities Challenges
Growing acceptance of generics Limited regulatory transparency
Opportunities under government policies promoting local production Need for quality investments
Potential export markets (regional) Capacity constraints

Key Regulations Favoring Local Manufacturing

  • Government incentives: tax breaks, import duties exemptions.
  • Local content requirements: mandated minimum production local content.
  • Price control policies: to keep medications affordable.

Comparison: Tunisia vs. Regional Markets

Aspect Tunisia Egypt South Africa
Market Size (2022) $430 million $2.2 billion $1.1 billion
Regulatory Stringency Moderate Moderate–high High
Local Manufacturing Presence Small but growing Significant Established
Generic Market Penetration 35% 40–50% 45–55%
Investment Climate Emerging Improving Mature

Note: Tunisia’s market remains less mature relative to Egypt and South Africa but exhibits promising growth potential.

Opportunities in Biosimilars and Innovative Drugs

  • Biosimilars: Regulatory absence but planned establishment by 2025 offers opportunities.
  • Innovative Drugs: Adoption driven by private sector and specialized hospitals.
  • Collaborations: Partnerships with European and Asian biotech firms can facilitate market entry.

Key Challenges to Consider

Challenge Mitigation Strategies
Regulatory delays and uncertainty Engage early with OCT; monitor policy updates
Limited manufacturing capacity Invest in local facilities; leverage government incentives
Pricing pressures Develop differentiated value propositions
Insufficient local R&D Partner with universities; seek government grants
Market fragmentation Focus on niche therapeutic areas

Policy and Strategic Recommendations

  1. Stakeholder Engagement: Close dialogue with MoH and OCT to influence regulatory reforms.
  2. Local Production Investment: Capitalize on government incentives and local market growth.
  3. Quality & Compliance: Prioritize adherence to WHO standards to facilitate regional exports.
  4. Bioequivalence Capabilities: Develop in-house testing for generics to reduce approval time.
  5. Regional Expansion: Evaluate export potentials within Africa, leveraging regional trade agreements.

Key Takeaways

  • Market Growth: Tunisia’s pharmaceutical market is projected to grow at approximately 4.2%, with generics constituting a significant and expanding segment.
  • Regulatory Environment: Progressive but requires modernization to attract more investment, especially in biosimilars and innovative medicines.
  • Opportunities: Local manufacturing, biosimilar development, private sector expansion, and regional exports.
  • Challenges: Regulatory delays, capacity constraints, price controls, and market fragmentation.
  • Strategic Focus: Stakeholder engagement, investment in quality infrastructure, and partnerships are critical to capitalizing on market opportunities.

FAQs

Q1: What are the main regulatory hurdles for pharmaceutical companies entering Tunisia?
A: Lengthy approval timelines, limited bioequivalence testing capacity, and evolving standards pose challenges for market entry and speed to market.

Q2: How does Tunisia’s generic drug market compare to neighboring countries?
A: Tunisia’s generic penetration (~35%) is modest but expected to grow; its regulatory framework is less mature than Egypt but offers opportunities, especially with upcoming reforms.

Q3: Are biosimilars a viable opportunity in Tunisia?
A: Yes; with planned regulatory frameworks arriving by 2025, biosimilars hold potential, especially given regional demand for affordable biologic therapies.

Q4: What incentives does the Tunisian government offer to local pharmaceutical manufacturers?
A: Tax incentives, import duty exemptions, local content requirements, and support for capacity expansion to promote indigenous production.

Q5: How can foreign companies mitigate risks related to market access in Tunisia?
A: Engage in early regulatory dialogue, partner with local firms, invest in quality infrastructure, and align products with local policies focusing on affordability and access.

References

[1] Tunisian Ministry of Health, 2022 Data.
[2] IQVIA Tunisia Pharmaceutical Market Reports, 2022.
[3] World Health Organization, Regional Office for Africa, 2023.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links